Working… Menu

Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01718379
Recruitment Status : Completed
First Posted : October 31, 2012
Last Update Posted : November 8, 2016
Roche Pharma AG
Information provided by (Responsible Party):
Groupe Francophone des Myelodysplasies